These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6226910)

  • 41. Comparison between subcutaneous and intravenous DDAVP in mild and moderate hemophilia A.
    De Sio L; Mariani G; Muzzucconi MG; Chistolini A; Tirindelli MC; Mandelli F
    Thromb Haemost; 1985 Aug; 54(2):387-9. PubMed ID: 3936212
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Case report: successful use of antifibrinolytic therapy in acquired factor VIII deficiency.
    Lalwani RB; Stricker RB
    Am J Med Sci; 1992 Jun; 303(6):398-401. PubMed ID: 1605170
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Consideration in the dental treatment of the hemophiliac patient.
    Evans BE
    J Dent Guid Counc Handicap; 1976; 15(2):3-7. PubMed ID: 160426
    [No Abstract]   [Full Text] [Related]  

  • 44. DDAVP (desmopressin) in the dental management of patients with mild or moderate hemophilia and von Willebrand's disease.
    Vierrou AM; de la Fuente B; Poole AE; Hoyer LW
    Pediatr Dent; 1985 Dec; 7(4):297-301. PubMed ID: 2938080
    [No Abstract]   [Full Text] [Related]  

  • 45. New ways to boost factor VIII in hemophilia: DDAVP for mild hemophilia A, von Willebrand's.
    Marwick C
    JAMA; 1983 Jun; 249(24):3278-9. PubMed ID: 6406692
    [No Abstract]   [Full Text] [Related]  

  • 46. [The position of a vasopressin derivative ("DDAVP") in the treatment of haemophilia A (author's transl)].
    Blättler W; Jacky E; Müller M; Graf M; Meili E
    Ther Umsch; 1979 Apr; 36(4):330-3. PubMed ID: 377557
    [No Abstract]   [Full Text] [Related]  

  • 47. Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety.
    Lethagen S
    Semin Thromb Hemost; 2003 Feb; 29(1):101-6. PubMed ID: 12640572
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Acquired hemophilia A as a cause of postoperative bleeding].
    Leimkühler K; Bach F; Kobert K; Korth M; Schmidt B; Kulbe C; Gummelt I; Mertzlufft F
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2003 May; 38(5):359-65. PubMed ID: 12712401
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epsilon-aminocaproic acid inhibits the activity of factor VIII inhibitors in patients with severe haemophilia A in vivo and in vitro.
    Ghosh K; Shetty S; Pathare A; Mohanty D
    Acta Haematol; 2000; 103(2):67-72. PubMed ID: 10838448
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Desmopressin (DDAVP) for treatment of disorders of hemostasis.
    Mannucci PM
    Prog Hemost Thromb; 1986; 8():19-45. PubMed ID: 3104987
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epsilon aminocaproic acid in hemophiliacs undergoing dental extractions: a concise review.
    Lucas ON; Albert TW
    Oral Surg Oral Med Oral Pathol; 1981 Feb; 51(2):115-20. PubMed ID: 6782532
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 1-Deamino-8-D-arginine vasopressin in the treatment of non-haemophilic patients with acquired factor VIII inhibitor.
    Muhm M; Grois N; Kier P; Stümpflen A; Kyrle P; Pabinger I; Bettelheim P; Hinterberger W; Lechner K
    Haemostasis; 1990; 20(1):15-20. PubMed ID: 2108912
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The dental management of patients with spontaneous acquired factor VIII inhibitors.
    Hasson DM; Poole AE; de la Fuente B; Hoyer LW
    J Am Dent Assoc; 1986 Oct; 113(4):633-6. PubMed ID: 2945852
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dental management of the classic hemophiliac with inhibitors.
    Redding SW; Stiegler KE
    Oral Surg Oral Med Oral Pathol; 1983 Aug; 56(2):145-8. PubMed ID: 6225980
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical efficacy of desmopressin in the treatment of mild hemophilia A in children].
    Bai ST; Lu J; Sheng GY; Xu ST; Xie L; Peng S
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Sep; 13(9):715-7. PubMed ID: 21924018
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes.
    Suzuki H; Shima M; Arai M; Kagawa K; Fukutake K; Kamisue S; Nakai H; Morichika S; Tanaka I; Inoue M; Gale K; Tuddenham EG; Yoshioka A
    Thromb Haemost; 1997 May; 77(5):862-7. PubMed ID: 9184393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dental management of the patient with hemophilia.
    Katz JO; Terezhalmy GT
    Oral Surg Oral Med Oral Pathol; 1988 Jul; 66(1):139-44. PubMed ID: 2970054
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of activated prothrombin complex concentrate in a severely hemophilic patient with Factor VIII inhibitor.
    Garehime WJ; Pecaro BC; Green D
    J Oral Maxillofac Surg; 1983 Apr; 41(4):262-4. PubMed ID: 6220139
    [No Abstract]   [Full Text] [Related]  

  • 60. Response of patients with hemophilia A and von Willebrand disease to desmopressin (DDAVP).
    Santiago-Borrero PJ; Casanova R
    Bol Asoc Med P R; 1990 May; 82(5):207-10. PubMed ID: 2115785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.